CA3203202A1 - Nanobody to glycoprotein vi - Google Patents

Nanobody to glycoprotein vi

Info

Publication number
CA3203202A1
CA3203202A1 CA3203202A CA3203202A CA3203202A1 CA 3203202 A1 CA3203202 A1 CA 3203202A1 CA 3203202 A CA3203202 A CA 3203202A CA 3203202 A CA3203202 A CA 3203202A CA 3203202 A1 CA3203202 A1 CA 3203202A1
Authority
CA
Canada
Prior art keywords
nanobody
gpvi
binding
antigen binding
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3203202A
Other languages
English (en)
French (fr)
Inventor
Alexandre SLATER
Natalie Sarah Poulter
Mark Robert Thomas
Steve Paul Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Birmingham
Original Assignee
University of Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Birmingham filed Critical University of Birmingham
Publication of CA3203202A1 publication Critical patent/CA3203202A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3203202A 2020-12-24 2021-12-21 Nanobody to glycoprotein vi Pending CA3203202A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2020602.5A GB202020602D0 (en) 2020-12-24 2020-12-24 Nanobody
GB2020602.5 2020-12-24
PCT/EP2021/087129 WO2022136457A1 (en) 2020-12-24 2021-12-21 Nanobody to glycoprotein vi

Publications (1)

Publication Number Publication Date
CA3203202A1 true CA3203202A1 (en) 2022-06-30

Family

ID=74532190

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3203202A Pending CA3203202A1 (en) 2020-12-24 2021-12-21 Nanobody to glycoprotein vi

Country Status (7)

Country Link
US (1) US20240067721A1 (cg-RX-API-DMAC7.html)
EP (1) EP4267624A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024500946A (cg-RX-API-DMAC7.html)
CN (1) CN117043191A (cg-RX-API-DMAC7.html)
CA (1) CA3203202A1 (cg-RX-API-DMAC7.html)
GB (1) GB202020602D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022136457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019685A1 (en) * 2024-07-17 2026-01-22 Harpoon Therapeutics, Inc. Her2 targeting trispecific protein for treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130543D0 (en) * 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
US20090130021A1 (en) * 2002-06-07 2009-05-21 Gotz Munch Methods, products and uses involving platelets and/or the vasculature
WO2007091719A1 (ja) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 抗gpvi抗体の併用療法及び新規医薬用途
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
JP5843783B2 (ja) * 2009-12-18 2016-01-13 サノフイ GPVIに対する新規アンタゴニスト抗体および該抗体のFabフラグメントならびにこれらの使用

Also Published As

Publication number Publication date
CN117043191A (zh) 2023-11-10
EP4267624A1 (en) 2023-11-01
WO2022136457A1 (en) 2022-06-30
US20240067721A1 (en) 2024-02-29
JP2024500946A (ja) 2024-01-10
GB202020602D0 (en) 2021-02-10

Similar Documents

Publication Publication Date Title
JP7668256B2 (ja) Dll3及びcd3に結合する二重特異性抗体構築物
KR102700015B1 (ko) 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
KR102944460B1 (ko) Cldn18.2 및 cd3에 대한 항체 작제물
KR102914586B1 (ko) 메소텔린 및 cd3에 결합하는 이중특이적 항체 작제물
JP6959011B2 (ja) Bcmaおよびcd3に対する二重特異性を有するt細胞エンゲージ抗体コンストラクト
KR102735615B1 (ko) Egfrviii 및 cd3에 결합하는 이중특이적 항체 작제물
AU2016250023B2 (en) Bispecific antibody constructs for CDH3 and CD3
JP7785450B2 (ja) Muc17及びcd3に向けられる二重特異性抗体コンストラクト
KR20260028110A (ko) 이중특이성 t 세포 맞물림 항체 작제물
RS66465B1 (sr) Inhibitorna monoklonska antitela protiv faktora xii/xiia i njihove upotrebe
US12617863B2 (en) Humanized anti-glycoprotein Ib alpha (GPIbalpha) antibodies
AU2019338955B2 (en) Bispecific antibody targeting IL-1R1 and NLRP3
US20210214435A1 (en) Antibodies targeting glycoprotein vi
US20240067721A1 (en) Nanobody to glycoprotein vi
CA3188566A1 (en) Coagulation factor xi (fxi) binding protein
WO2020243228A1 (en) Antibodies to polyphosphate decrease fibrosis
US20200048333A1 (en) Antigen-binding domains of the monoclonal anti-collagen i antibody
US20250051452A1 (en) Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
CN120173111B (zh) 一种抗血小板GPIb-IX抗体及其应用
JP2025533434A (ja) 二重特異性分子安定化組成物
HK40130468A (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
EA046884B1 (ru) Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260622